Use of Metformin for Ovulation Induction in Women Who Have Polycystic Ovary Syndrome With or Without Evidence of Insulin Resistance

Journal of Obstetrics and Gynaecology Canada

Volumn 28, Issue 7, 2006, Pages 595-599

  Liu, Kimberly E ^a   Tataryn, Ivanna Viola ^a   Sagle, Margaret ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Metformin; Ovulation induction; Polycystic ovary syndrome

Indexed keywords

GLUCOSE; INSULIN; METFORMIN; TESTOSTERONE; ANTIDIABETIC AGENT;

ADULT; ANOVULATION; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FEMALE INFERTILITY; FOLLOW UP; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; OBESITY; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PREGNANCY RATE; RETROSPECTIVE STUDY; BLOOD; GLUCOSE BLOOD LEVEL; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; PREGNANCY;

ADULT; BLOOD GLUCOSE; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; METFORMIN; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY RATE; RETROSPECTIVE STUDIES;

EID: 33748650249     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)32202-2     Document Type: Article

References (37)

1. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004, 81:19-25. Revised 2003.
2. Female infertility: treatment options for complicated cases The ESHRE Capri Workshop. European Society for Human Reproduction and Embryology. Hum Reprod 1997, 12:1191-1196.
3. Infertility revisited: the state of the art today and tomorrow The ESHRE Capri Workshop. European Society for Human Reproduction and Embryology. Hum Reprod 1996, 11:1779-1807.
4. Nasseri S., Ledger W.L. Clomiphene citrate in the twenty-first century. Hum Fertil (Camb ) 2001, 4:145-151.
5. Lord J.M., Flight I.H., Norman R.J. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003, 327:951-953. 25-10-2003.
6. Kashyap S., Wells G.A., Rosenwaks Z. Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome. Hum Reprod 2004, 19:2474-2483.
7. Palomba S., Orio F., Falbo A., Manguso F., Russo T., Cascella T., et al. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005, 90:4068-4074.
8. Maciel G.A., Soares J.M., Alves da Motta E.L., Abi H.M., de Lima G.R., Baracat E.C. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril 2004, 81:355-360.
9. Kumari A.S., Haq A., Jayasundaram R., Abdel-Wareth L.O., Al Haija S.A., Alvares M. Metformin monotherapy in lean women with polycystic ovary syndrome. Reprod Biomed Online 2005, 10:100-104.
10. Vandermolen D.T., Ratts V.S., Evans W.S., Stovall D.W., Kauma S.W., Nestler J.E. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 2001, 75:310-315.
11. Kocak M., Caliskan E., Simsir C., Haberal A. Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. Fertil Steril 2002, 77:101-106.
12. George S.S., George K., Irwin C., Job V., Selvakumar R., Jeyaseelan V., et al. Sequential treatment of metformin and clomiphene citrate in clomiphene-resistant women with polycystic ovary syndrome: a randomized, controlled trial. Hum Reprod 2003, 18:299-304.
13. Palomba S., Orio F., Nardo L.G., Falbo A., Russo T., Corea D., et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. J Clin Endocrinol Metab 2004, 89:4801-4809.
14. Malkawi H.Y., Qublan H.S., Hamaideh A.H. Medical vs. surgical treatment for clomiphene citrate-resistant women with polycystic ovary syndrome. J Obstet Gynaecol 2003, 23:289-300.
15. Lord J.M., Flight I.H., Norman R.J. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003, CD003053.
16. Nestler J.E., Jakubowicz D.J., Evans W.S., Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. NEJM 1998, 338:1876-1880.
17. Sahin Y., Yirmibes U., Kelestimur F., Aygen E. The effects of metformin on insulin resistance, clomiphene-induced ovulation and pregnancy rates in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2004, 113:214-220. 15-4-2004.
18. Dunaif A., Segal K.R., Futterweit W., Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989, 38:1165-1174.
19. Deugarte C.M., Bartolucci A.A., Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 2005, 83:1454-1460.
20. Legro R.S., Finegood D., Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998, 83:2694-2698.
21. Ciampelli M., Leoni F., Cucinelli F., Mancuso S., Panunzi S., De Gaetano A., et al. Assessment of insulin sensitivity from measurements in the fasting state and during an oral glucose tolerance test in polycystic ovary syndrome and menopausal patients. J Clin Endocrinol Metab 2005, 90:1398-1406.
22. Moghetti P., Castello R., Negri C., Tosi F., Perrone F., Caputo M., et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6 month trial, followed by open, long term clinical evaluation. J Clin Endocrinol Metab 2000, 85:139-146.
23. Costello M.F., Eden J.A. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril 2003, 79:1-13.
24. Sills E.S., Perloe M., Palermo G.D. Correction of hyperinsulinemia in oligoovulatory women with clomiphene-resistant polycystic ovary syndrome: a review of therapeutic rationale and reproductive outcomes. Eur J Obstet Gynecol Reprod Biol 2000, 91:135-141.
25. Nardo L.G., Rai R. Metformin therapy in the management of polycystic ovary syndrome: endocrine, metabolic and reproductive effects. Gynecol Endocrinol 2001, 15:373-380.
26. La Marca A., Morgante G., Paglia T., Ciotta L., Cianci A., De L.V. Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome. Fertil Steril 1999, 72:985-989.
27. De Leo V., La Marca A., Orvieto R., Morgante G. Effect of metformin on insulin-like growth factor (IGF) I and IGF-binding protein I in polycystic ovary syndrome. J Clin Endocrinol Metab 2000, 85:1598-1600.
28. Nestler J.E., Jakubowicz D.J. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996, 335:617-623. 29-8-1996.
29. Nestler J.E., Jakubowicz D.J. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab 1997, 82:4075-4079.
30. Ben Haroush A., Yogev Y., Fisch B. Insulin resistance and metformin in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2004, 115:125-133. 10-8-2004.
31. Ehrmann D.A., Breda E., Cavaghan M.K., Bajramovic S., Imperial J., Toffolo G., et al. Insulin secretory responses to rising and falling glucose concentrations are delayed in subjects with impaired glucose tolerance. Diabetologia 2002, 45:509-517.
32. El Mkadem S.A., Lautier C., Macari F., Molinari N., Lefebvre P., Renard E., et al. Role of allelic variants Gly972Arg of IRS-1 and Gly1057Asp of IRS-2 in moderate-to-severe insulin resistance of women with polycystic ovary syndrome. Diabetes 2001, 50:2164-2168.
33. Dunaif A., Xia J., Book C.B., Schenker E., Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995, 96:801-810.
34. Ciaraldi T.P., el Roeiy A., Madar Z., Reichart D., Olefsky J.M., Yen S.S. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab 1992, 75:577-583.
35. Consensus Development Conference on Insulin Resistance American Diabetes Association. Diabetes Care 1998, 21:310-314. 5-6 November 1997.
36. Sheehan M.T. Polycystic Ovarian Syndrome: Diagnosis and Management. Clin Med Res 2004, 2:13-27.
37. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403. 7-2-2002.